$IKT
Inhibikase Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021974 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $116.4K $64.52K $46.03K
YoY Change 1676.71% 40.17% -96.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.783M $1.925M $1.670M
YoY Change 7.14% 15.32% 4.31%
% of Gross Profit
Research & Development $4.536M $2.854M $3.017M
YoY Change 52.09% -5.4% 24.06%
% of Gross Profit
Depreciation & Amortization $159.2K $5.043K $0.00
YoY Change
% of Gross Profit
Operating Expenses $6.319M $4.779M $4.687M
YoY Change 35.99% 1.98% 16.22%
Operating Profit -$6.202M -$4.715M -$4.641M
YoY Change 33.67% 1.6% 76.77%
Interest Expense $424.4K $237.2K $5.00
YoY Change 4743300.0% -99.96%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.778M -$4.478M -$4.641M
YoY Change 24.53% -3.51% 75.78%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.778M -$4.478M -$4.641M
YoY Change 24.53% -3.51% 75.98%
Net Earnings / Revenue -4963.46% -6940.03% -10081.47%
Basic Earnings Per Share -$1.11 -$0.16 -$0.18
Diluted Earnings Per Share -$1.11 -$0.16 -$184.1K
COMMON SHARES
Basic Shares Outstanding 31.06M 28.98M 25.23M
Diluted Shares Outstanding 5.226M 27.51M 25.21M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.94M $25.72M $36.61M
YoY Change -35.01% -29.75% 280.97%
Cash & Equivalents $1.905M $3.957M $36.61M
Short-Term Investments $19.03M $21.76M
Other Short-Term Assets $969.2K $1.846M $1.730M
YoY Change -44.0% 6.68% -10.34%
Inventory
Prepaid Expenses $425.2K $923.1K $565.3K
Receivables $79.60K $64.52K $47.98K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $21.98M $27.63M $38.39M
YoY Change -35.25% -28.03% 223.38%
LONG-TERM ASSETS
Property, Plant & Equipment $86.52K $231.5K
YoY Change 100.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $363.6K $534.8K -$4.00
YoY Change 743.87% -13368900.0% -100.14%
TOTAL ASSETS
Total Short-Term Assets $21.98M $27.63M $38.39M
Total Long-Term Assets $363.6K $534.8K -$4.00
Total Assets $22.35M $28.16M $38.39M
YoY Change -34.26% -26.64% 223.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $754.1K $959.1K $806.2K
YoY Change -12.35% 18.96% 12.75%
Accrued Expenses $1.831M $1.558M $3.574M
YoY Change -49.56% -56.4% 469.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $2.733M $2.664M $4.380M
YoY Change -39.13% -39.18% 22.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $150.0K $178.1K
YoY Change
Total Long-Term Liabilities $150.0K $178.1K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.733M $2.664M $4.380M
Total Long-Term Liabilities $150.0K $178.1K $0.00
Total Liabilities $2.883M $2.842M $4.380M
YoY Change -35.79% -35.11% 14.14%
SHAREHOLDERS EQUITY
Retained Earnings -$58.13M -$52.35M -$34.46M
YoY Change 48.67% 51.92% 95.02%
Common Stock $77.59M $77.50M $68.47M
YoY Change 13.11% 13.2% 166.36%
Preferred Stock
YoY Change
Treasury Stock (at cost) $196.0K $385.9K
YoY Change -37.63%
Treasury Stock Shares
Shareholders Equity $19.46M $25.32M $34.01M
YoY Change
Total Liabilities & Shareholders Equity $22.35M $28.16M $38.39M
YoY Change -34.26% -26.64% 223.31%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$5.778M -$4.478M -$4.641M
YoY Change 24.53% -3.51% 75.98%
Depreciation, Depletion And Amortization $159.2K $5.043K $0.00
YoY Change
Cash From Operating Activities -$4.565M -$5.972M -$3.934M
YoY Change 4.81% 51.8% 0.0%
INVESTING ACTIVITIES
Capital Expenditures $14.24K
YoY Change -133.05%
Acquisitions
YoY Change
Other Investing Activities $2.564M -$5.839M
YoY Change
Cash From Investing Activities $2.550M -$5.839M $0.00
YoY Change -6017.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -35.98K 8.579M -204.8K
YoY Change -4289.61% -50.02%
NET CHANGE
Cash From Operating Activities -4.565M -5.972M -3.934M
Cash From Investing Activities 2.550M -5.839M 0.000
Cash From Financing Activities -35.98K 8.579M -204.8K
Net Change In Cash -2.051M -3.232M -4.139M
YoY Change -53.36% -21.91% -4.72%
FREE CASH FLOW
Cash From Operating Activities -$4.565M -$5.972M -$3.934M
Capital Expenditures $14.24K
Free Cash Flow -$4.580M
YoY Change 6.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2023Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiability
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001750149
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P3Y
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39676
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
INHIBIKASE THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3407249
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3350 Riverwood Parkway SE
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1900
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30339
CY2023Q1 dei City Area Code
CityAreaCode
678
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
392-3419
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
IKT
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31056238
CY2023Q1 us-gaap Cash
Cash
3956604
CY2022Q4 us-gaap Cash
Cash
7188553
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
21761564
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
15861620
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
64521
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
39881
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
923128
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1117616
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
922764
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
163452
CY2023Q1 us-gaap Assets Current
AssetsCurrent
27628581
CY2022Q4 us-gaap Assets Current
AssetsCurrent
24371122
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
231489
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236532
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
303263
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
328643
CY2023Q1 us-gaap Assets
Assets
28163333
CY2022Q4 us-gaap Assets
Assets
24936297
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
959078
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1151173
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
146901
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
145836
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1558221
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2398436
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2664200
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3695445
CY2023Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
178110
CY2022Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
205451
CY2023Q1 us-gaap Liabilities
Liabilities
2842310
CY2022Q4 us-gaap Liabilities
Liabilities
3900896
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31056238
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31056238
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25227051
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25227051
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
31056
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25227
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
77473765
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68777298
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
165822
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
104718
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52349620
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47871842
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
25321023
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21035401
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28163333
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24936297
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64521
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46031
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64521
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46031
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2854119
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3016991
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1925351
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1669636
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
4779470
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
4686627
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4714949
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4640596
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
237171
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4477778
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4640601
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
61104
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4416674
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4640601
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27510077
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27510077
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25205454
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25205454
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21035401
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
123273
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
8579023
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
61104
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4477778
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
25321023
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38415549
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
123229
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
67000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44142
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4640601
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
34009319
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4477778
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4640601
CY2023Q1 us-gaap Depreciation
Depreciation
5043
CY2022Q1 us-gaap Depreciation
Depreciation
0
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
123273
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
123229
CY2023Q1 ikt Non Cash Consulting Fees
NonCashConsultingFees
0
CY2022Q1 ikt Non Cash Consulting Fees
NonCashConsultingFees
67000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
24638
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-62165
CY2023Q1 ikt Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
25380
CY2022Q1 ikt Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
759312
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-337653
CY2023Q1 ikt Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
-194488
CY2022Q1 ikt Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
458301
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-192095
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-283582
CY2023Q1 ikt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
26276
CY2022Q1 ikt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-840215
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
858240
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5972130
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3934197
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21611032
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2023Q1 ikt Maturities Of Investments Marketable Securitie
MaturitiesOfInvestmentsMarketableSecuritie
15772190
CY2022Q1 ikt Maturities Of Investments Marketable Securitie
MaturitiesOfInvestmentsMarketableSecuritie
0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5838842
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44142
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8579023
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
248911
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8579023
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-204769
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3231949
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4138966
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7188553
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40750133
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3956604
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36611167
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
973
CY2023Q1 ikt Issuance Costs
IssuanceCosts
1420398
CY2022Q1 ikt Issuance Costs
IssuanceCosts
0
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inhibikase Therapeutics, Inc. (the “Company,” “we” or “our”) is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease ("PD"), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. The Company’s multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program utilizing IkT-148009, a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. In 2021, we commenced clinical development of IkT-148009, which we believe can modify the course of Parkinson’s disease including its manifestation in the gastrointestinal tract, or GI. The U.S. Food and Drug Administration (“FDA”) review of the Phase 1/1b data and the protocol for the Phase 2a three-month dosing study resulted in the FDA agreeing with the Company’s view that it was appropriate for the Phase 2a study to begin, prompting the Company to initiate the Phase 2a study, the 201 trial, at the end of May 2022. In October 2022, an IND to expand use of IkT-148009 into the Parkinson’s-related disease Multiple System Atrophy, or MSA, was filed with the FDA. On November 7, 2022, following review of the IND for IkT-148009 as a treatment for MSA, the FDA notified the Company that it was placing the IkT-148009 programs for Parkinson’s disease and MSA on clinical hold. The FDA lifted the full clinical hold in January 2023 for the Parkinson’s programs and in March 2023 on the MSA program, opening the IND for MSA. 20 of 36 planned sites have completed site opening procedures and 7 sites are currently screening patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients. Our first example of this technology is IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate, to treat Stable Phase Chronic Myelogenous Leukemia (SP-CML). Pursuant to its IND, which was cleared by the FDA in August 2022, IkT-001Pro is being evaluated in a two-part dose finding/dose equivalence study in up to 59 healthy volunteers (the 501 trial). The study is designed to evaluate the 96-hour pharmacokinetics of imatinib delivered as IkT-001Pro and determine the dose of IkT-001Pro that can deliver the equivalent 400 mg imatinib, the standard-of-care dose for SP-CML. As of the date of this Report, four of four dose escalation cohorts have completed the trial. Only four mild adverse events have been observed, none of clinical significance for IkT-001Pro. IkT-001Pro has high oral bioavailability and a pharmacokinetic profile of delivered imatinib that closely matches the exposure of imatinib delivered as 400 mg imatinib mesylate. Following the 501 study, Inhibikase will confer with the FDA and seek agreement on the requirements for the New Drug Application (“NDA”) process following the proposed approval path for IkT-001Pro under the 505(b)(2) approval pathway. The Company plans to simultaneously pursue a superiority study comparing the selected doses of IkT-001Pro to standard-of-care 400 mg imatinib in SP-CML patients using a novel, two-period-wait-list-crossover-switching study.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> For both IkT-148009 and IkT-001Pro, we have completed clinical batch manufacturing of a film-coated tablet formulation. The bioequivalence studies with IkT-001Pro have already implemented these tablets into the study.</span></p>
CY2023Q1 ikt Working Capital
WorkingCapital
24964381
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52349620
CY2023Q1 us-gaap Cash
Cash
3956604
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
21761564
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2664200
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
195982
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.733%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of our liquidity and working capital adequacy, the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.733%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended March 31, 2023 and 2022, the Company d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">erived </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of its to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tal revenue from a single source, the United States Government, in the form of federal research grants.</span></p>
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
243255
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
11766
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21595742
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
165822
CY2023Q1 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
21761564
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15756902
CY2022 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
104718
CY2022 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
15861620
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15700000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4960000
CY2023Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2022 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
243255
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
6723
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
231489
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236532
CY2023Q1 us-gaap Depreciation
Depreciation
5043
CY2022 us-gaap Depreciation
Depreciation
6723
CY2023Q1 ikt Accrued Consulting Current
AccruedConsultingCurrent
423464
CY2022Q4 ikt Accrued Consulting Current
AccruedConsultingCurrent
232390
CY2023Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
283657
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
459997
CY2023Q1 ikt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
851000
CY2022Q4 ikt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1696129
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9920
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1558221
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2398436
CY2023Q1 ikt Common Stock Per Share Entitled To Vote
CommonStockPerShareEntitledToVote
1
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24221725
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3028398
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8.6
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
123273
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
123229
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4477778
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4640601
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27510077
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27510077
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25205454
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25205454
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24221725
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5409313
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
146901
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
178110
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
35296
CY2023Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
5788
CY2022Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
19063
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
109643
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
150095
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
114966
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
374704
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49693
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
325011
CY2023Q1 us-gaap Subsequent Event Description
SubsequentEventDescription
On January 24, 2023 and July 25, 2022, we received written notices from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that based upon the closing bid price of the Company’s common stock, for the 30 consecutive business days prior to the notice, the Company no longer met the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). On January 24, 2023, the Company received notice from Nasdaq indicating that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180-day period, or until July 24, 2023, to regain compliance. According to the notice from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for the market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Minimum Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this second 180-day compliance period, the closing bid price of the common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance.
CY2023Q1 ikt Closing Price Of Common Stock
ClosingPriceOfCommonStock
1.00
CY2023Q1 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
10

Files In Submission

Name View Source Status
0000950170-23-021974-index-headers.html Edgar Link pending
0000950170-23-021974-index.html Edgar Link pending
0000950170-23-021974.txt Edgar Link pending
0000950170-23-021974-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ikt-20230331.htm Edgar Link pending
ikt-20230331.xsd Edgar Link pending
ikt-ex31_1.htm Edgar Link pending
ikt-ex31_2.htm Edgar Link pending
ikt-ex32_1.htm Edgar Link pending
ikt-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
ikt-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ikt-20230331_def.xml Edgar Link unprocessable
ikt-20230331_lab.xml Edgar Link unprocessable
ikt-20230331_pre.xml Edgar Link unprocessable
ikt-20230331_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending